{"id":"https://openalex.org/W4393073226","doi":"https://doi.org/10.1158/1538-7445.am2024-4575","title":"Abstract 4575: FGFR3 altered bladder cancer exhibits a lineage-dependent vulnerability","display_name":"Abstract 4575: FGFR3 altered bladder cancer exhibits a lineage-dependent vulnerability","publication_year":2024,"publication_date":"2024-03-22","ids":{"openalex":"https://openalex.org/W4393073226","doi":"https://doi.org/10.1158/1538-7445.am2024-4575"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2024-4575","doi":"https://doi.org/10.1158/1538-7445.am2024-4575","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.am2024-4575","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5083812516","display_name":"Mohamad Karim Koleilat","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mohamad Karim Koleilat","raw_affiliation_strings":["1UT MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1UT MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062469302","display_name":"Yan Yu Zhu","orcid":"https://orcid.org/0000-0002-3347-3045","observed_orcids":["https://orcid.org/0000-0002-3347-3045"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yan Zhu","raw_affiliation_strings":["1UT MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1UT MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5040776645","display_name":"Lawrence N. Kwong","orcid":"https://orcid.org/0000-0001-8370-1432","observed_orcids":["https://orcid.org/0000-0001-8370-1432"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lawrence Kwong","raw_affiliation_strings":["1UT MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1UT MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"84","issue":"6_Supplement","first_page":"4575","last_page":"4575"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.7407000064849854,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.7407000064849854,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12287","display_name":"Fibroblast Growth Factor Research","score":0.2401999980211258,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11287","display_name":"Cancer Genomics and Diagnostics","score":0.0017000000225380063,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/fgfr3","display_name":"FGFR3","score":0.7490000128746033},{"id":"https://openalex.org/keywords/bladder-cancer","display_name":"bladder cancer","score":0.9449999928474426},{"id":"https://openalex.org/keywords/erdafitinib","display_name":"erdafitinib","score":0.9620000123977661},{"id":"https://openalex.org/keywords/mediator-complex","display_name":"Mediator complex","score":0.7269999980926514},{"id":"https://openalex.org/keywords/cyclin-c","display_name":"cyclin C","score":0.8619999885559082},{"id":"https://openalex.org/keywords/gata3","display_name":"GATA3","score":0.8629999756813049},{"id":"https://openalex.org/keywords/ppargamma","display_name":"PPAR\u03b3","score":0.9990000128746033},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.5080000162124634},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.8410000205039978},{"id":"https://openalex.org/keywords/crispr-screening","display_name":"CRISPR screen","score":0.6869999766349792},{"id":"https://openalex.org/keywords/cell-of-origin","display_name":"cell of origin","score":0.6309999823570251},{"id":"https://openalex.org/keywords/mapk-signaling","display_name":"MAPK signaling","score":0.5920000076293945}],"concepts":[{"id":"https://openalex.org/C95713431","wikidata":"https://www.wikidata.org/wiki/Q631425","display_name":"Vulnerability (computing)","level":2,"score":0.6883728504180908},{"id":"https://openalex.org/C2780352672","wikidata":"https://www.wikidata.org/wiki/Q504775","display_name":"Bladder cancer","level":3,"score":0.6409032344818115},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5430561304092407},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.514079213142395},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4221607446670532},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3216969966888428},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.056381404399871826},{"id":"https://openalex.org/C38652104","wikidata":"https://www.wikidata.org/wiki/Q3510521","display_name":"Computer security","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2024-4575","doi":"https://doi.org/10.1158/1538-7445.am2024-4575","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.am2024-4575","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4225275090","https://openalex.org/W4401715237","https://openalex.org/W2049151386","https://openalex.org/W4415444593","https://openalex.org/W4408724856","https://openalex.org/W2740618410","https://openalex.org/W4404159607","https://openalex.org/W4402974541","https://openalex.org/W3125469825","https://openalex.org/W4322487704"],"abstract_inverted_index":{"Abstract":[0],"Fibroblast":[1],"Growth":[2],"Factor":[3],"3":[4,205],"(FGFR3)":[5],"genomic":[6],"alterations":[7],"are":[8],"oncogenic":[9],"drivers":[10],"in":[11,25,90,120,144,155,178,211,243,276,307,333,358,367,381],"~15%":[12],"of":[13,38,43,50,111,116,130,162,216,224,229,248,258,320,340,346,410],"bladder":[14,78,280,374,401],"cancer":[15,79,402],"patients.":[16],"A":[17],"novel":[18],"FGFR":[19,274],"inhibitor,":[20],"Erdafitinib,":[21,295],"was":[22,142,158],"FDA":[23],"approved":[24],"2019":[26],"based":[27],"off":[28],"a":[29,48,63,87,104,127,193,264,270,284,324,379,404],"Phase":[30],"II":[31],"trial":[32],"with":[33,236,263,269,365,370],"an":[34,74,241,353],"overall":[35],"response":[36],"rate":[37],"40%.":[39],"However,":[40],"the":[41,112,135,153,167,256,327,334,411],"majority":[42],"patients":[44,369],"rapidly":[45],"relapse":[46],"at":[47],"median":[49],"6":[51],"months,":[52],"requiring":[53],"combination":[54],"therapies":[55],"to":[56,92,160,188,191,199,222,273,292,311,387],"prevent":[57],"drug":[58],"resistance.":[59],"We":[60,71,202,282],"hypothesized":[61],"that":[62,161,214,255,288],"genome-wide":[64],"CRISPR":[65,180],"screen":[66],"would":[67],"identify":[68],"Erdafitinib-sensitizing":[69],"co-targets.":[70],"screened":[72],"UM-UC-14,":[73],"S249C":[75],"FGFR3":[76,122,277,371,399],"mutated":[77],"cell":[80,124,147],"line,":[81],"and":[82,99,109,134,173,209,227,323,355],"identified":[83,378],"Cyclin":[84,101],"C":[85,102],"as":[86,97,207,385],"top":[88],"hit":[89],"addition":[91],"known":[93],"MAPK":[94],"effectors":[95],"such":[96],"ERK2":[98],"SHP2.":[100],"is":[103,267],"non-cell":[105],"cycle":[106],"related":[107],"cyclin":[108],"part":[110],"CDK8/19":[113,136,361],"kinase":[114],"module":[115],"Mediator.":[117],"Pharmacological":[118],"validation":[119],"4":[121],"altered":[123,400],"lines":[125],"confirmed":[126],"high":[128],"degree":[129],"synergy":[131,154],"between":[132],"Erdafitinib":[133,366],"inhibitor":[137,164,169],"Sel120,":[138],"while":[139],"no":[140,338],"effect":[141],"seen":[143],"2":[145],"wildtype":[146],"lines,":[148],"suggesting":[149],"strong":[150,271],"specificity.":[151],"Moreover,":[152],"FGFR3-mutant":[156],"cells":[157,213,234],"superior":[159],"SHP2":[163,363],"SHP099":[165],"or":[166,219,343,362],"ERK":[168],"BVD-523.":[170],"Similarly,":[171],"GATA3":[172,218],"PPARG":[174,220],"also":[175],"scored":[176],"highly":[177],"our":[179,252],"screen.":[181],"These":[182],"transcription":[183],"factors":[184],"have":[185],"been":[186],"shown":[187],"be":[189],"sufficient":[190],"enforce":[192],"luminal":[194,212,225,249],"identity":[195],"but":[196,296],"not":[197,330],"necessarily":[198],"maintain":[200],"it.":[201],"validated":[203],"these":[204],"genes":[206],"sensitizers":[208,386],"show":[210],"loss":[215,223,247,339],"either":[217,360],"leads":[221],"markers":[226,245],"gain":[228,257],"basal":[230,244,259],"markers.":[231,250],"In":[232],"contrast,":[233,302],"treated":[235],"Sel120":[237],"showed,":[238],"on":[239],"RNAseq,":[240],"increase":[242],"without":[246,297],"Interestingly,":[251],"data":[253],"suggests":[254],"markers,":[260],"commonly":[261],"associated":[262,268],"worse":[265],"prognosis,":[266],"sensitization":[272],"inhibition":[275],"alteration":[278,372],"driven":[279,373],"cancer.":[281],"conducted":[283],"xenograft":[285],"experiment":[286],"confirming":[287],"mice":[289,309,313],"responded":[290],"well":[291],"single":[293],"agent":[294],"frank":[298],"tumor":[299],"regression.":[300],"By":[301],"Sel120+Erdafitinib":[303],"induced":[304],"complete":[305,335],"responses":[306],"8/10":[308],"compared":[310],"6/10":[312],"for":[314,414],"SHP099+Erdafitinib.":[315],"Remarkably,":[316],"after":[317],"60":[318],"days":[319],"daily":[321],"drugging":[322],"20-day":[325],"washout,":[326],"tumors":[328],"did":[329],"grow":[331],"back":[332],"responders.":[336],"Importantly,":[337],"body":[341],"weight":[342],"other":[344],"signs":[345],"morbidity":[347],"were":[348],"found.":[349],"Our":[350],"results":[351],"suggest":[352],"immediate":[354],"promising":[356],"benefit":[357],"combining":[359],"inhibitors":[364],"treating":[368],"cancers.":[375],"Furthermore,":[376],"we":[377],"strategy":[380],"targeting":[382],"lineage":[383],"modulators":[384],"existing":[388],"therapies.":[389],"Citation":[390],"Format:":[391],"Mohamad":[392],"Karim":[393],"Koleilat,":[394],"Yan":[395],"Zhu,":[396],"Lawrence":[397],"Kwong.":[398],"exhibits":[403],"lineage-dependent":[405],"vulnerability":[406],"[abstract].":[407],"In:":[408],"Proceedings":[409],"American":[412],"Association":[413],"Cancer":[415,433],"Research":[416],"Annual":[417],"Meeting":[418],"2024;":[419],"Part":[420],"1":[421],"(Regular":[422],"Abstracts);":[423],"2024":[424],"Apr":[425],"5-10;":[426],"San":[427],"Diego,":[428],"CA.":[429],"Philadelphia":[430],"(PA):":[431],"AACR;":[432],"Res":[434],"2024;84(6_Suppl):Abstract":[435],"nr":[436],"4575.":[437]},"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2024-03-23T00:00:00"}